Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2170360 | 0.82 | CA12 (0.42) | KDM4ECA1CA2CA9LMNA | |
| SCHEMBL15845321 | 0.82 | CYP3A4 (0.58) | SMN1; SMN2LMNATP53HRH3ALDH1A1 | |
| SCHEMBL9501750 | 0.80 | GABRA1 (0.37) | SMN1; SMN2RXRARXRBPOLB | |
| SCHEMBL513003 | 0.80 | ALDH1A1 (0.49) | CA1CA2CA9MAOBAOC3 | |
| SCHEMBL10707563 | 0.80 | ACACB (0.39) | SMN1; SMN2KDM4ECA1CA2CA9 | |
| SCHEMBL15604421 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2APPNR4A2RXRARXRB | |
| SCHEMBL5104116 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2APPNR4A2RXRARXRB | |
| SCHEMBL7909459 | 0.79 | SMN1; SMN2 (0.47) | SMN1; SMN2APPNR4A2RXRARXRB | |
| SCHEMBL23911695 | 0.77 | SMN1; SMN2 (0.47) | SMN1; SMN2APPNR4A2RXRARXRB | |
| SCHEMBL514644 | 0.77 | L3MBTL1 (0.47) | LMNANPC1L3MBTL1MAOBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 568 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117924393-A | Monomer of 3' -mercapto nucleoside analogue and its synthesis process | 天津兴博润生物制药有限公司 | 2024-04-26 | — | — | CN | claimed |
| US-20230014840-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | NIPPON SHINYAKU CO., LTD. (JP) | 2023-01-19 | — | — | US | claimed |
| US-20230018780-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | NIPPON SHINYAKU CO., LTD. (JP) | 2023-01-19 | — | — | US | claimed |
| CN-115397831-A | Compositions comprising nucleic acid oligomers | 住友化学株式会社 | 2022-11-25 | — | — | CN | claimed |
| CN-114981280-A | Method for producing oligonucleotide compound | 日本新药株式会社 | 2022-08-30 | — | — | CN | claimed |
| CN-114981281-A | Method for producing oligonucleotide compound | 日本新药株式会社 | 2022-08-30 | — | — | CN | claimed |
| US-20210206809-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | VERA THERAPEUTICS INC (US) | 2021-07-08 | — | — | US | claimed |
| WO-2021095875-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | 日本新薬株式会社 | 2021-05-20 | — | — | WO | claimed |
| WO-2021095874-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | 日本新薬株式会社 | 2021-05-20 | — | — | WO | claimed |
| US-20200318109-A1 | LNA-G Process | F. HOFFMANN-LA ROCHE AG (CH) | 2020-10-08 | — | — | US | claimed |
| US-6750335-B2 | NUCLEOSIDE FOR USE IN THE GENERATION OF PREFERENTIAL OLIGONUCEOTIDES | NIGU CHEMIE GMBH (DE) | 2004-06-15 | — | — | US | claimed |
| EP-1006121-B1 | A universal polymer support for the synthesis of oligonucleotides | COUNCIL SCIENT IND RES (IN) | 2003-05-02 | — | — | EP | claimed |
| EP-1224198-B1 | NUCLEOSIDE DERIVATIVES WITH PHOTOLABILE PROTECTING GROUPS | NIGU CHEMIE GMBH (DE) | 2003-04-23 | — | — | EP | claimed |
| US-6541626-B2 | Protecting/blocking the exocyclic amino function of purine nucleosides without effecting hydroxyl groups of sugar moieties via forming activated ester | ISIS PHARMACEUTICALS, INC. | 2003-04-01 | — | — | US | claimed |
| US-20030022862-A1 | Process for selective N-acylation of purine nucleosides | ALLAHABAD, UNIVERSITY OF (IN) | 2003-01-30 | — | — | US | claimed |
| WO-2002083702-A1 | PROCESS FOR SELECTIVE N-ACYLATION OF PURINE NUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | WO | claimed |
| US-6075143-A | USEFUL FOR FORMING PEPTIDE NUCLEIC ACIDS OR HYBRID OF PEPTIDE NUCLEIC ACIDS AND DEOXYNUCLEIC ACID | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-06-13 | — | — | US | claimed |
| EP-1006121-A1 | A universal polymer support for the synthesis of oligonucleotides | Council of Scientific and Industrial Research (IN) | 2000-06-07 | — | — | EP | claimed |
| US-5817811-A | AMIDATION OF THE CORRESPOND ESTERIFIED AMINE COMPOUND WITH A CARBOXYLATED NUCLEOTIDE BASE | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-10-06 | — | — | US | claimed |
| EP-0672661-A1 | Substituted N-ethyl-glycinderivatives for the preparation of PNA and PNA-/DNA hybrides | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-09-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200318109-A1 | LNA-G Process | OGG1, DUT, FBL | SMN1; SMN2 606/4885APP 2843/4885NR4A2 2722/4885 |
| US-20230018780-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | POLRMT, POLR2H, POLM | SMN1; SMN2 1263/4885APP 2814/4885NR4A2 4469/4885 |
| US-20030022862-A1 | Process for selective N-acylation of purine nucleosides | PNP, NUDT1, ADAR | SMN1; SMN2 1207/4885APP 4466/4885NR4A2 3268/4885 |
| US-20210206809-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | AGO2, TARBP1, TPR | SMN1; SMN2 840/4885APP 1769/4885NR4A2 2464/4885 |
| US-20230014840-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | DNASE1, XRN2, FBL | SMN1; SMN2 1489/4885APP 2036/4885NR4A2 3618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.